We undertook a randomized clinical trial comparing therapeutic efficacy of the 1-day doxycycline regimen with the 5-day josamycin regimen for Mediterranean spotted fever. All 59 patients recovered uneventfully, and results did not significantly differ between the two schedules. One-day doxycycline therapy is an effective, easy, and inexpensive treatment. Josamycin is a useful therapeutic alternative that may be particularly convenient for pregnant women and patients with a history of allergy to tetracyclines.
for pregnant women and patients with a history of allergy to tetracyclines.
Mediterranean spotted fever is a tick-borne rickettsiosis caused by Rickettsia conorii (2) . Tetracyclines are presently the drugs of choice for treatment of the disease, and among them doxycycline has shown advantages because of its antirickettsial activity (8) and pharmacokinetics. In a previous study of adult patients with Mediterranean spotted fever, two single doses of doxycycline have proven to be as effective as the classic 10-day tetracycline hydrochloride regimen (1) . However, tetracyclines may cause untoward effects, particularly in children under the age of 8, pregnant women, and patients allergic to tetracyclines. The activity of chloramphenicol is similar to those of tetracyclines, but occurrences of aplastic anemia have led to restriction of the use of this drug. The potential usefulness of the new quinolone compounds has been recently reported (4, 6) , although quinolones should not be prescribed for pregnant women or for children. Erythromycin has poor in vitro antimicrobial activity against R. conorii (8) and has been shown to be less effective than tetracyclines for treating boutonneuse fever (5) . In vitro evaluation of josamycin against Rickettsia rickettsii and R. conorii has shown that this macrolide antibiotic may be of clinical use in treating spotted fever rickettsiosis (7) . (Table 2) . Differences between the two groups were not statistically significant. One patient in each group had side effects (gastrointestinal symptoms), but in none of them was suspension of the trial necessary. When only the 32 children (ages, 2 to 13 years) included in the study were considered, no significant differences between the groups were found.
The present study confirmed the usefulness of the 1-day doxycycline course for treating Mediterranean spotted fever in children, as has been previously established for adults (1) . To our knowledge, this therapeutic regimen has not been used previously for children; however, the results we obtained with these shorter regimens are at least as good as those reported previously with a 10-day regimen (5 childhood [3] ). So, we consider 1-day doxycyline to be the regimen of choice for children. Raoult et al. (7) evaluated the activity ofjosamycin against R. conorii and R. rickettsii in two tests: a dye uptake assay and a plaque assay. Both assays determined a josamycin MIC of 1 ,ug/ml for both strains. Before the onset of this trial, seven children with Mediterranean spotted fever received josamycin at conventional doses (25 mg/kg of body weight at 12-h intervals), and fever disappeared after 3.7 ± 1.7 days of treatment. One adult patient was also given josamycin (1 g every 12 h for 5 days), and fever disappeared after 7 days of therapy; the total duration of the fever was 12 days. These observations prompted us to use higher doses of josamycin (3 g/day in adults and 100 mg/kg of body weight per day in children). From the good results obtained and the excellent tolerance to such doses that was observed in the present study, it may be inferred that josamycin is a useful therapeutic alternative in cases of Mediterranean spotted fever. It may also prove to be particularly convenient in treating pregnant women and patients with a history of allergy to tetracycline compounds.
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